12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pegasys peginterferon alfa-2a: Phase III

In a 531-patient open-label international Phase III study comparing 180 ug Pegasys once weekly to interferon alfa-2a three times per week, sustained virologic responses were 39 and...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >